A review of erlotinib and its clinical use

作者：Tang PA; Tsao MS; Moore MJ

来源：Expert Opinion on Pharmacotherapy, 2006, 7(2): 177-193.

DOI：10.1517/146566.7.2.177

• erlotinib
• non-small cell lung cancer
• pancreatic cancer
• squamous cell cancer of the head and neck

Erlotinib is an orally available, reversible tyrosine kinase inhibitor of the epidermal growth factor receptor. Encouraging activity as a single agent and in corn bination with other targeted agents has been demonstrated in Phase 11 trials in many tumour types. Erlotinib has an established role in the treatment of advanced, refractory non-small cell lung cancer-based on a pivotal trial demonstrating a survival advantage over best supportive care. In a Phase III trial, the addition of erlotinib to gemcitabine improved survival in advanced pancreatic cancer. The toxicity profile of erlotinib includes diarrhoea and rash, with no haematological side effects. Predictive factors for response include the presence of a rash, epidermal growth factor receptor expression and mutation status. This article reviews the current clinical status of erlotinib.

• 出版日期2006-2